Physician profile
Jonathan Ray Hall
NPI 1083173769
$1,076.28
in general payments reported to CMS, 2019-2025
12 companies · $429 in 2025
The $429 reported for 2025 was more than what 96% of Nurse Anesthetist, Certified Registered providers received nationally (typical 2025 total: $45.72).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $253 · 2024: $394 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,076.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $181.33 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.51 | 2023-2025 | Xifaxan, Trulance, Plenvu |
| Ardelyx, INC. | $157.09 | 2023-2025 | Ibsrela |
| Abbvie INC. | $106.55 | 2023-2025 | |
| Janssen Biotech, INC. | $97.34 | 2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $73.72 | 2023-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $58.21 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $54.70 | 2024-2025 | Resmetirom, Rezdiffra |
| Merck Sharp & Dohme LLC | $46.70 | 2023-2024 | Dificid |
| Lilly USA, LLC | $44.43 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $43.55 | 2023-2025 | Sutab, Suflave |
| Aimmune Therapeutics, INC. | $33.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.